Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.07
▼(-12.50% Downside)
Action:DowngradedDate:01/27/26
The score is held down primarily by weak financial performance (pre-revenue characteristics, ongoing losses, and continued cash burn) combined with elevated balance-sheet leverage. Technicals also reflect recent weakness (negative MACD; price below key short/intermediate moving averages). Corporate actions around financing and debt milestones provide some support, but they are offset by ongoing dependence on capital markets and dilution risk; valuation signals are limited due to negative earnings.
Positive Factors
Management incentive alignment
Tying CEO equity vesting to conversion/repayment milestones aligns leadership incentives with balance-sheet repair and deleveraging. Over months this should focus management on securing durable financing, reducing leverage, and executing capital-structure fixes that improve long-term financial flexibility and governance.
Negative Factors
Pre-revenue with persistent losses
The company remains effectively pre-revenue with ongoing operating losses, leaving no internal revenue engine to fund R&D or operations. Over the next several months this limits self-sufficiency, forces continued external capital needs, and keeps profitability distant absent clear clinical or commercial progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Management incentive alignment
Tying CEO equity vesting to conversion/repayment milestones aligns leadership incentives with balance-sheet repair and deleveraging. Over months this should focus management on securing durable financing, reducing leverage, and executing capital-structure fixes that improve long-term financial flexibility and governance.
Read all positive factors
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.20M
Dividend YieldN/A
Average Volume (3M)410.07K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth65.22%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding442,596,600
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-19.12
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-39.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase ...
How the Company Makes Money
Oncotelic Therapeutics primarily generates revenue through the development and commercialization of its therapeutic candidates. The company's revenue model includes securing funding through partnerships, grants, and licensing agreements with other...
Oncotelic Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 | 1.74M |
| Gross Profit | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K | 1.74M |
| EBITDA | -863.01K | -3.55M | -7.16M | -5.60M | -9.06M | -7.61M |
| Net Income | -1.67M | -4.52B | -7.90M | 17.82M | -11.39M | -11.50M |
Balance Sheet | ||||||
| Total Assets | 28.16M | 26.68M | 30.01M | 36.12M | 23.61M | 23.66M |
| Cash, Cash Equivalents and Short-Term Investments | 409.00K | 86.13K | 170.41K | 241.45K | 568.77K | 474.02K |
| Total Debt | 17.41M | 13.09M | 12.57M | 11.26M | 8.99M | 5.43M |
| Total Liabilities | 20.08M | 19.20M | 18.40M | 16.92M | 15.45M | 11.18M |
| Stockholders Equity | 9.05M | 8.25M | 12.13M | 19.41M | 7.96M | 11.77M |
Cash Flow | ||||||
| Free Cash Flow | -704.01K | -740.27K | -1.32M | -1.45M | -4.43M | -2.81M |
| Operating Cash Flow | -704.01K | -740.27K | -1.32M | -1.45M | -4.43M | -2.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 964.00K | 656.00K | 1.25M | 1.13M | 4.53M | 3.22M |
Oncotelic Therapeutics Technical Analysis
Neutral
0.08
Price Trends
0.05
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
43.72
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.72 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 35 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncotelic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $79.38M | -4.61 | -10.61% | ― | ― | 45.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $50.06M | 0.54 | -225.83% | ― | -14.92% | 72.81% | |
46 Neutral | $17.20M | -7.84 | -38.38% | ― | ― | 65.22% | |
46 Neutral | $18.23M | ― | -1041.79% | ― | ― | 1.18% | |
40 Underperform | $9.21M | -3,346.34 | -526.36% | ― | ― | -2.46% | |
| ― | $80.69M | -3.39 | -3.76% | ― | ― | 44.50% |
* Healthcare Sector Average
OTLC
Oncotelic Therapeutics
0.04
-0.02
-33.33%
GRCE
Grace Therapeutics
5.13
3.33
185.00%
LTRN
Lantern Pharma
1.62
-1.19
-42.35%
CALC
CalciMedica
0.59
-1.23
-67.68%
ELUT
Elutia
1.17
-1.41
-54.65%
MAIA
MAIA Biotechnology, Inc.
1.33
-0.13
-8.90%
Oncotelic Therapeutics Corporate Events
Private Placements and Financing
Oncotelic Therapeutics Secures Convertible Debt Financing Agreement
Neutral
Jan 29, 2026
On January 23, 2026, Oncotelic Therapeutics secured $398,333 in convertible debt from Mast Hill Fund, issuing a one-year, 10% secured note convertible at $0.07 per share, together with 1,422,613 warrants at $0.15, and restricted the use of proceed...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Oncotelic Therapeutics Ties CEO Equity to Debt Milestones
Positive
Jan 26, 2026
On January 22, 2026, Oncotelic Therapeutics, Inc. entered into a restricted stock agreement with chief executive officer Dr. Vuong Trieu that ties his equity compensation to specific capital-structure improvement milestones. The company will issue...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Oncotelic Therapeutics Lowers Milestone Thresholds to Aid Uplisting
Positive
Jan 7, 2026
On January 6, 2026, Oncotelic Therapeutics, Inc. announced amendments to an independent contractor agreement with Jefferson Capital Ventures, LLC, originally dated August 6, 2025, and to a restricted stock award agreement dated November 17, 2025, ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Oncotelic revises incentive agreement to support financing strategy
Positive
Jan 6, 2026
On December 31, 2025, Oncotelic Therapeutics, Inc. amended its independent contractor agreement with Jefferson Capital Ventures, LLC, changing the threshold for Jefferson to earn restricted stock awards from a market capitalization milestone of $1...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Therapeutics completes final tranche of private financing
Positive
Jan 6, 2026
On December 31, 2025, Oncotelic Therapeutics, Inc. completed the third and final tranche of a private offering, issuing 44 units to 22 accredited investors under subscription agreements, while two prior investors holding a total of seven units fro...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic completes private convertible note and warrant financing
Positive
Dec 30, 2025
On December 23, 2025, Oncotelic Therapeutics, Inc. completed subscription agreements with 21 accredited investors for 32 units in a private offering of up to 500 units, each consisting of a $25,000, 12% two-year note convertible into either Oncote...
Business Operations and StrategyProduct-Related Announcements
Oncotelic Therapeutics Launches PDAOAI Biomedical Data Platform
Positive
Dec 23, 2025
On December 22, 2025, Oncotelic Therapeutics, Inc. announced that it had opened access to PDAOAI, its proprietary evidence-interrogation platform built to extract biologically meaningful signals from large, complex biomedical datasets without the ...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Therapeutics Completes Subscription Agreement with Investors
Neutral
Dec 9, 2025
On December 4, 2025, Oncotelic Therapeutics completed a subscription agreement with accredited investors, issuing 11 units as part of a larger offering of up to 500 units. Each unit includes a note convertible into shares of Oncotelic or its subsi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.